630 related articles for article (PubMed ID: 32208432)
1. Impact of vaccination on measles, mumps, and rubella antibody titers in Japanese healthcare workers: An observational study.
Ogawa T; Inoue T; Kasahara K; Konishi M; Mikasa K
PLoS One; 2020; 15(3):e0230329. PubMed ID: 32208432
[TBL] [Abstract][Full Text] [Related]
2. Rubella virus neutralizing antibody response after a third dose of measles-mumps-rubella vaccine in young adults.
McLean HQ; Fiebelkorn AP; Ogee-Nwankwo A; Hao L; Coleman LA; Adebayo A; Icenogle JP
Vaccine; 2018 Sep; 36(38):5732-5737. PubMed ID: 30107992
[TBL] [Abstract][Full Text] [Related]
3. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up.
Carryn S; Feyssaguet M; Povey M; Di Paolo E
Vaccine; 2019 Aug; 37(36):5323-5331. PubMed ID: 31345639
[TBL] [Abstract][Full Text] [Related]
4. Pre-vaccination IgG screening for mumps is the most cost-effectiveness immunization strategy among Health Care Workers.
Coppeta L; Balbi O; Baldi S; Pietroiusti A; Magrini A
Hum Vaccin Immunother; 2019; 15(5):1135-1138. PubMed ID: 30779686
[TBL] [Abstract][Full Text] [Related]
5. Rubella virus-specific humoral immune responses and their interrelationships before and after a third dose of measles-mumps-rubella vaccine in women of childbearing age.
Haralambieva IH; Ovsyannikova IG; Kennedy RB; Goergen KM; Grill DE; Chen MH; Hao L; Icenogle J; Poland GA
Vaccine; 2020 Jan; 38(5):1249-1257. PubMed ID: 31732325
[TBL] [Abstract][Full Text] [Related]
6. [Antibody persistence following on different vaccination strategies of domestic measles, mumps and rubella combined attenuated live vaccine: a 3-year follow-up study].
He HQ; Li Q; Yan R; Zhou Y; Tang XW; Deng X; Xie SY; Chen ZP
Zhonghua Yu Fang Yi Xue Za Zhi; 2017 Apr; 51(4):336-340. PubMed ID: 28395468
[No Abstract] [Full Text] [Related]
7. Open randomized trial comparing the immunogenicity and safety of a new measles-mumps-rubella vaccine and a licensed vaccine in 12- to 24-month-old children.
Feiterna-Sperling C; Brönnimann R; Tischer A; Stettler P; Durrer P; Gaedicke G
Pediatr Infect Dis J; 2005 Dec; 24(12):1083-8. PubMed ID: 16371870
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study.
Abu-Elyazeed R; Jennings W; Severance R; Noss M; Caplanusi A; Povey M; Henry O
Hum Vaccin Immunother; 2018; 14(11):2624-2631. PubMed ID: 29902133
[TBL] [Abstract][Full Text] [Related]
10. Antibody persistence in children aged 6-7years one year following booster immunization with two MMR vaccines applied by aerosol or by injection.
Díaz Ortega JL; Castaneda D; Arellano Quintanilla DM; Martínez D; Trumbo SP; Fernández de Castro J
Vaccine; 2017 May; 35(23):3116-3122. PubMed ID: 28457672
[TBL] [Abstract][Full Text] [Related]
11. 10-Year survey on serum antibody positivity rates and titers for measles and rubella in healthcare workers; an observational study at a Japanese university hospital.
Yoshioka N; Deguchi M; Hagiya H; Kagita M; Tsukamoto H; Takao M; Yoshida H; Hamaguchi S; Maeda I; Hidaka Y; Tomono K
J Infect Chemother; 2021 Sep; 27(9):1295-1299. PubMed ID: 33910777
[TBL] [Abstract][Full Text] [Related]
12. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months.
Kontio M; Palmu AA; Syrjänen RK; Lahdenkari M; Ruokokoski E; Davidkin I; Vaarala O; Melin M
J Infect Dis; 2016 Jun; 213(12):2005-13. PubMed ID: 26908733
[TBL] [Abstract][Full Text] [Related]
13. Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines.
Schwarzer S; Reibel S; Lang AB; Struck MM; Finkel B; Gerike E; Tischer A; Gassner M; Glück R; Stück B; Cryz SJ
Vaccine; 1998; 16(2-3):298-304. PubMed ID: 9607046
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of measles, rubella, mumps, and varicella antibodies among healthcare workers in Japan.
Hatakeyama S; Moriya K; Itoyama S; Nukui Y; Uchida M; Shintani Y; Morisawa Y; Kimura S
Infect Control Hosp Epidemiol; 2004 Jul; 25(7):591-4. PubMed ID: 15301032
[TBL] [Abstract][Full Text] [Related]
15. Long-term Immunogenicity of Measles Vaccine: An Italian Retrospective Cohort Study.
Bianchi FP; Stefanizzi P; De Nitto S; Larocca AMV; Germinario C; Tafuri S
J Infect Dis; 2020 Feb; 221(5):721-728. PubMed ID: 31580436
[TBL] [Abstract][Full Text] [Related]
16. Changes in the prevalence of the measles, rubella, varicella-zoster, and mumps virus antibody titers in Japanese pregnant women.
Hanaoka M; Hisano M; Watanabe N; Sugawara K; Kambe Y; Kanda E; Sago H; Kato T; Yamaguchi K
Vaccine; 2013 May; 31(19):2343-7. PubMed ID: 23523405
[TBL] [Abstract][Full Text] [Related]
17. Measles, mumps, and rubella antibody patterns of persistence and rate of decline following the second dose of the MMR vaccine.
Seagle EE; Bednarczyk RA; Hill T; Fiebelkorn AP; Hickman CJ; Icenogle JP; Belongia EA; McLean HQ
Vaccine; 2018 Feb; 36(6):818-826. PubMed ID: 29317117
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.
Nakayama T; Eda M; Hirano M; Goto W
Hum Vaccin Immunother; 2019; 15(5):1139-1144. PubMed ID: 30724658
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.
Ceyhan M; Kanra G; Erdem G; Kanra B
Vaccine; 2001 Aug; 19(31):4473-8. PubMed ID: 11483273
[TBL] [Abstract][Full Text] [Related]
20. Prevaccination antibody screening and immunization program for healthcare personnel against measles, mumps, rubella, and varicella in a Japanese tertiary care hospital.
Kanamori H; Tokuda K; Ikeda S; Endo S; Ishizawa C; Hirai Y; Takahashi M; Aoyagi T; Hatta M; Gu Y; Yano H; Weber DJ; Kaku M
Tohoku J Exp Med; 2014 Oct; 234(2):111-6. PubMed ID: 25224029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
